Bae SH

No ORCID on file · 4 papers in corpus
other 2026
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist
Clinical pharmacokinetics ·doi:10.1007/s40262-025-01595-0

Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/ph…

2025
Surgically confirmed severe endometriosis is associated with lower risk of steatotic liver disease: Evidence of Estrogen-Linked Hepatic–Reproductive Crosstalk
·doi:10.22541/au.175915278.82899661/v1

Objective: The prevalence of steatotic liver disease (SLD) is rising globally, while endometriosis is a leading cause of infertility. Although links with metabolic syndrome have been reported, its relationship with SLD remains unclear. We …

2024
Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.
Frontiers in immunology ·doi:10.3389/fimmu.2024.1444100

BackgroundMetabolic dysfunction-associated steatohepatitis (MASH) is characterized by persistent inflammatory cascades, with macrophage activation playing a pivotal role. Chitinase 1 (CHIT1), produced by activated macrophages, is a key play…

article 2015
Uterine Artery Embolization for Adenomyosis: Percentage of Necrosis Predicts Midterm Clinical Recurrence
Journal of vascular and interventional radiology : JVIR ·doi:10.1016/j.jvir.2015.04.026

PurposeTo evaluate the effect of degree of necrosis after uterine artery embolization (UAE) on symptom recurrence at midterm clinical follow-up in patients with adenomyosis.Materials and methodsWomen (N = 50) who underwent UAE for symptomat…